ADVANCES IN LUNG CANCER TREATMENTS
|
|
- Leslie Norman
- 6 years ago
- Views:
Transcription
1 ADVANCES IN LUNG CANCER TREATMENTS Joan H. Schiller, MD Deputy Director of Clinical Research; Chief of Hematology/Oncology Inova Schar Cancer Institute; Fairfax, VA Chair of the Scientific Steering Committee, LCRF
2 A very special thank you to our partners
3 Hope through advances in lung cancer treatments Lung cancer continues to be the single largest cancer killer of men and women in the US 1 Research remains very much underfunded BUT, there is HOPE Important advances are being made in lung cancer diagnosis and treatment 1. American Cancer Society. Cancer Facts & Figures Atlanta: American Cancer Society; American Cancer Society. Cancer Facts & Figures 2018.
4 Research is the driver of change in the treatment of lung cancer Basis for changing clinical practice and improving outcomes: FDA approvals New drugs New ways to use existing drugs Removal of approval of drugs or specific uses of drugs Changes to the National Comprehensive Cancer Network (NCCN) Guidelines Help determine clinical practice, ie, how patients are treated Usually quickly updated in response to FDA approvals FDA approvals, NCCN guidelines, and other recommendations are driven by research
5 We are making progress: Key FDA approvals Chemotherapy Targeted therapies FDA approvals of new drugs EGFR ROS1 ALK BRAF Immunotherapy T790M 2018 Lung Cancer Research Foundation FDA.gov.
6 New research findings incorporated into NCCN guidelines Increase in frequency of updates of guidelines due to: New drugs Research on how best to use approved drugs New tumor testing techniques 1/2016 1/2017: Five updates for NSCLC In 2017, five updates by March 2017 Already in 2018, two versions issued for both NSCLC and small cell lung cancer (as of Jan 23)! 1,2 1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology (NCCN guidelines ) Nonsmall Cell Lung Cancer. Version Published December 19, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology (NCCN guidelines ) Small Cell Lung Cancer. Version Published January 17, 2018.
7 Targeted therapies
8 Targeted therapies are specific for the particular protein or gene that is altered in the tumor 2017 Free to Breathe
9 Efficacy of an EGFR inhibitor (erlotinib) 6 FEB FEB Kim ES, et al. Personalized care for metastatic NSCLC: Practical application of research advances and emerging data. Educational Concepts Group, LLC; 2014.
10 Scientific story behind EGFR-targeted treatments An initial discovery Identification of EGFR overexpression in lung cancer 1. Ke EE, Wu YL. Trends Pharmacol Sci Nov;37(11): onclive.com/publications/oncology-live/2016/vol-17-no-3/egfr-inhibitors-continue-march-in-mutated-nsclc?p=4
11 Scientific story behind EGFR-targeted treatments Research continues to lead to new treatments and help refine how best to use treatments 1. Ke EE, Wu YL. Trends Pharmacol Sci Nov;37(11): onclive.com/publications/oncology-live/2016/vol-17-no-3/egfr-inhibitors-continue-march-in-mutated-nsclc?p=4
12 Currently approved EGFR-targeted therapies Uncommon mutations (S768I, L861Q, and/or G719X) Disease progression Tumor testing or liquid biopsy T790M 1. FDA.gov. 2. Melosky B, et al. Clin Lung Cancer. 2018;19(1): Osimertinib Afatinib/ Gilotrif Erlotinib/Tarceva Gefitinib/Iressa Osimertinib/Tagrisso
13 Anticipated change for EGFR-targeted therapies Uncommon mutations (S768I, L861Q, and/or G719X) Disease progression Tumor testing or liquid biopsy T790M Osimertinib moving to 1 st line Osimertinib 1. FDA.gov. 2. Melosky B, et al. Clin Lung Cancer. 2018;19(1):42-50.
14 What s new in EGFR-targeted therapies? FLAURA trial shows that osimertinib improved progression-free survival (PFS) vs erlotinib or gefitinib, in previouslyuntreated patients with locally-advanced or metastatic EGFR-mutated NSCLC September NCCN guidelines include osimertinib as 1st-line treatment of patients with EGFR-mutated mnsclc based on FLAURA December FDA accepts application of osimertinib as 1 st -line treatment based on FLAURA Osimertinib blocks EGFR-sensitizing and EGFR T790M-resistance mutations Source: NEJM Quick Takes 1. FDA.gov. 2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology (NCCN guidelines ) Non-small Cell Lung Cancer. Version Published September 28, 2017.
15 FLAURA trial results Soria JC, et al. N Engl J Med. 2018;378(2): Source: NEJM Quick Takes
16 What s next: EGFR-targeting drugs? More studies to see which EGFR-targeting drugs should be used first and in what order (ie, sequencing) eg, GioTag is a real-world study to look at sequential therapy in patients with EGFR mutation-positive NSCLC Many new drugs in clinical trials AP32788 and poziotinib for EGFR exon 20 mutant NSCLC and exon 20 mutant NSCLC Clinicaltrials.gov.
17 ALK inhibitors DB PET Pre- and post Crizotinib 12/2011 ALK=anaplastic lymphoma kinase
18 ALK inhibitors DB PET Pre- and post Crizotinib 12/2011 3/2012 ALK=anaplastic lymphoma kinase
19 Efficacy of an ALK inhibitor (crizotinib) Pre-Treatment Crizotinib x 12 weeks Kim ES, et al. Personalized care for metastatic NSCLC: Practical application of research advances and emerging data. Educational Concepts Group, LLC;
20 FDA approved ALK inhibitors Approved for 1 st line Alectinib/Alecensa Ceritinib/Zykadia Crizotinib/Xalkori Approved for 2 nd line Brigatinib/Alunbrig New in 2017 Brigatinib A new ALK inhibitor Alectinib Approval as front-line therapy, based on ALEX trial Alectinib improved PFS by 47% vs crizotinib ALEX and J-ALEX are practice-changing clinical trials ALK=anaplastic lymphoma kinase 1. FDA.gov. 2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology (NCCN guidelines ) Non-small Cell Lung Cancer. Version Published January 17, 2018.
21 Alectinib as 1st-line therapy: ALEX study Image available at: alecensa.com/hcp/clinical-overview/first-line-efficacy.html Peters S, et al. N Engl J Med. 2017;377:
22 Alectinib as 1st-line therapy: ALEX study Time to cause-specific CNS progression (percentage of patients with CNS as first site of progression) Image available at: alecensa.com/hcp/clinical-overview/first-line-efficacy.html Peters S, et al. N Engl J Med. 2017;377:
23 Other news of ALK inhibitors Brigatinib continues to be studied as a first-line treatment versus crizotinib (ATLA-1L trial) Shows promising activity against resistance mutations 1 ASCEND-8 trial of optimal dosing of ceritinib to minimize side effects 2 A lower dose (450 mg/day ceritinib) taken with food can result in fewer GI side effects than 750 mg/day taken while fasting FDA approved new dosing (December 2017) 1. Zhang S, et al. Clin Cancer Res. 2016;22(22): Cho BC, et al. J Thorac Oncol. 2017;12(9):
24 ROS-1 inhibitors Crizotinib is approved for ROS-1 positive NSCLC Lorlatinib granted breakthrough therapy designation for use in patients with ALK-positive mnsclc (2017) Is a selective brain-penetrant ALK/ROS-1 inhibitor active against known resistance mutations Could be an option for patients who develop resistance after treatment with alectinib (ALK-positive NSCLC) Entrectinib granted orphan drug status for ROS-1 and ALK-positive lung cancer, and other rare cancers (2015) Designed to go across the blood-brain-barrier Ongoing studies to look at drugs to address brain metastasis 1. FDA.gov. 2. clinicaltrials.gov.
25 Available BRAF 600E inhibitors Dabrafenib/Tafinlar + Trametinib/Mekinist Treatment of patients with mnsclc expressing the BRAF V600E mutation First targeted treatment in the US specifically for BRAF V600E mutation-positive metastatic NSCLC June 2017 FDA approved the combination of dabrafenib and trametinib to treat patients whose tumors express the BRAF V600E mutation Patients with BRAF V600E mutation-positive metastatic NSCLC have responded less favorably to standard chemotherapy NCCN guidelines BRAF testing should be included as part of broad molecular profiling FDA.gov. mnsclc=metastatic non-small cell lung cancer
26 Other therapies Bevacizumab (Avastin ) and Ramucirumab (Cyramza ) Therapies that can stop angiogenesis, a process where the tumor makes new blood vessels Avastin is only used for patients who have nonsquamous NSCLC Necitumumab (Portrazza ) targets EGFR Necitumumab is only used for patients who have squamous NSCLC FDA.gov.
27 What s new in other treatments? IMpower150 trial Immunotherapy added to combo of chemo + bevacizumab (non-squamous NSCLC only) Promising early results* Atezolizumab + Carboplatin + Paclitaxel + Bevacizumab Median PFS, months Preliminary median overall survival*, months Atezolizumab + Carboplatin + Paclitaxel N/A N/A Carboplatin + Paclitaxel + Bevacizumab *Based on minimum 9.5 months of follow-up Reck M, et al, ESMO, 2017.
28 Advances in tumor testing NCCN guidelines include tumor testing for patients with adenocarcinoma for: EGFR mutations ALK gene rearrangements ROS-1 gene rearrangements BRAF V600E mutations PD-L1 testing might be done in patients considered for immunotherapy Studies continue to look at PD-L1 testing and other measures (eg, tumor mutation burden) Researchers hope tests will help identify which patients are likely to benefit from immunotherapy National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology (NCCN guidelines ) Small Cell Lung Cancer. Version Published January 17, 2018.
29 Advances in tumor testing: FDA approvals Liquid biopsy (test done on plasma) September 2016: Liquid biopsy for EGFR; osimertinib companion diagnostic for T790M June 2016: Liquid biopsy for EGFR; erlotinib companion diagnostic for exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR Next-generation sequencing (NGS) November 2017: FoundationOne CDx (F1CDx) is the first approved NGS-based test; can detect mutations in 324 genes and two genomic signatures in solid tumors CMS proposed coverage (final policies in progress) 1. FDA.gov. 2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology (NCCN guidelines ) Small Cell Lung Cancer. Version Published January 17, 2018.
30 Immunotherapy
31 Immune Cells Types of WBCs Neutrophils Important in fighting bacteria Macrophages Important in fighting any foreign substance Lymphocytes The generals of the immune system Several different types of lymphocytes Tell other immune cells what to do B-lymphocytes: Make antibodies Joan s oversimplified version of immunity and cancer Lymphocytes Lymphocytes Lymphocytes Lymphocytes T-Lymphocytes or T cells are important in fighting any foreign substance, such as cancer cells
32 What s supposed to happen: T-lymphocytes (T cells) monitor the body for things that aren t supposed to be there *Joan s embarrassingly overly simplified version of the immune system
33 What s supposed to happen: When T-cells recognize cancer cells as foreign = PD-1 *Joan s embarrassingly overly simplified version of the immune system
34 And become activated, allowing the T-cells to attack the tumor = PD-1 *Joan s embarrassingly overly simplified version of the immune system
35 What sometimes happens: Cancer cells make checkpoint proteins such as PD-L1 to mask the T- cells, by binding to PD-1 on the T cells, = PD-1 = PDL1 *Joan s embarrassingly overly simplified version of the immune system
36 What sometimes happens: Cancer cells make checkpoint proteins such as PD-L1 to mask the T-cells, by binding to PD-1 on the T cells, = PD-1 = PDL1 *Joan s embarrassingly overly simplified version of the immune system
37 What sometimes happens: Thus rendering the cancer cell invisible to the T cell* = PD-1 = PDL1 *Joan s embarrassingly overly simplified version of the immune system
38 What to do??? Anti-PD-1 antibodies stop the PD-L1 from binding to the PD-1 on T-cells Nivolumab, Pembrolizumab = PD-1 = Anti PD-1 *Joan s embarrassingly overly simplified version of the immune system
39 Anti-PD-L1 antibodies also stop PD-L1 from Binding to PD-1 on T-cells Atezolizumab, Durvalumab = PD-1 = Anti PD-L1 *Joan s embarrassingly overly simplified version of the immune system
40 Thus allowing the T-cells to see the cancer cell and attack = PD-1 = Anti PD-L1 *Joan s embarrassingly overly simplified version of the immune system
41 Longer survival for nivolumab vs docetaxel 1-3 Checkmate 017: Squamous mnsclc (N=272) Checkmate 057: Non-Squamous mnsclc (N=582) 1. Opdivo [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Brahmer J, et al. N Engl J Med. 2015;373: Borghaei H, et al. N Engl J Med. 73(17): Images available at:
42 CheckMate 057: 2 nd -line nivolumab vs docetaxel in non-squamous NSCLC Borghaei H, et al. N Engl J Med. 73(17):
43 Key advances October 2016 Immunotherapy moves to 1 st -line Pembrolizumab - first immunotherapy to be approved in first-line treatment for patients with NSCLC whose tumors have high PD-L1 expression with no EGFR or ALK aberrations May 2017 Immunotherapy combined with chemo Pembrolizumab - accelerated approval as first line treatment in combination with chemo (carboplatin + pemetrexed) for non-squamous NSCLC No PD-L1 testing required FDA.gov.
44 KEYNOTE 001: Pembrolizumab in chemo-naïve patients with NSCLC Survival of Patients Treated with Pembrolizumab by PD-L1 Expression PFS Higher PD-L1 expression Overall Survival Higher PD-L1 expression Garon EB et al. N Engl J Med 2015; 372(21):
45 Pembrolizumab + chemo in 1 st line Langer CJ, et al. Lancet Oncol. 2016;17(11):
46 FDA-approved immunotherapies Type Drug Use in first-line therapy? PD-1 inhibitor PD-L1 inhibitor Use with chemo? Use after chemo stops working? Requires PD-L1 testing? Nivolumab/ Opdivo No No Yes No Pembrolizumab/ Keytruda Yes Yes* Yes No** Yes Atezolizumab/ Tecentriq No No Yes No *Pembrolizumab is approved in combination with chemotherapy (pemetrexed and carboplatin) in patients with non-squamous NSCLC **When used with chemotherapy When used by itself for initial therapy (PD-L1 expression 50%) or after chemo stops working (PD-L1 expression 1%) These are not all of the FDA-approved indications FDA.gov.
47 Possible side effects of immunotherapy Part of the body Possible side effects Possible symptoms Lung Inflammation of the lungs (pneumonitis) Shortness of breath Cough Chest pain Intestine Inflammation of the colon (colitis) Diarrhea Pain in the stomach area Liver Inflammation of the liver (hepatitis) Dark urine Feeling less hungry Thyroid or other hormone glands Thyroid problems, such as underactive thyroid (hypothyroidism) Feeling cold Headaches Weight loss or gain Kidney Inflammation of the kidney (nephritis) Change in the amount or color of your urine Infusion reactions Skin or other organs Rash Eye problems Muscle problems Side effects related to IV administration Chills Fever These are not all the possible side effects of immunotherapy Rash or itching Rash Changes in eyesight Muscle pain or weakness Information obtained from Full Prescribing Information for approved immunotherapies available at FDA.gov.
48 Many more trials of immunotherapy Combinations Awaiting full results of KEYNOTE-189 trial of frontline pembrolizumab with pemetrexed (Alimta ) and either cisplatin or carboplatin New ways to use immunotherapy Neoadjuvant and adjuvant studies eg, LCMC 3 trial of atezolizumab before and after surgery New drugs under FDA review Durvalumab (Imfinzi ) after chemoradition in patients with stage 3 disease (Pacific trial) Studies of immunotherapy in small cell lung cancer (discussed in next sections)
49 PACIFIC trial may change clinical practice Active monitoring after chemoradiation was the standard of care for patients with locally advanced (Stage III) lung cancer whose tumors could not be removed by surgery PACIFIC trial looked at benefit of immunotherapy after chemoradiation Immunotherapy Patients with Stage III, locally advanced, unresectable NSCLC Chemoradiation treatment (CRT) Placebo Antonia SJ, et al. N Engl J Med. 2017;377(20):
50 Pacific Trial: PFS by BICR (Primary Endpoint; ITT) PFS probability Stratified hazard ratio, 0.52 (95% CI, ) Two-sided P< Durvalumab (N=476) Durvalumab 16.8 months Placebo 5.6 months Placebo (N=237) Median PFS (95% CI), months 16.8 ( ) 5.6 ( ) 12-month PFS rate (95% CI) 55.9% ( ) 35.3% ( ) 18-month PFS rate (95% CI) 44.2% ( ) 27.0% ( ) Time from randomization (months) Antonia SJ, et al. N Engl J Med. 2017;377(20): BICR, blinded independent central review; CI, confidence interval; ITT, intention-to-treat; PFS, progression-free survival
51 Practical issues in immunotherapy How best to select patients likely to respond Biomarkers: Does the amount of PD-1 or PD-L1 in a tumor matter? Measure them or not? Logistical issues with obtaining biomarkers What about tumor mutation burden? Optimal dosing How long to give? Understanding hyperprogression Cost
52 Tumor mutation burden (TMB) TMB is a measure of mutations carried by a tumor Determined by the number of mutations in a specific area of genetic material, such as mutations: In a single cell In an entire tumor Per area of building blocks of DNA Potential marker of sensitivity to immunotherapy Higher TMB may mean more likely to respond to immunotherapy Hot off the press (2/2018): CheckMate-227 showed that TMB is a predictive biomarker that can identify people with NSCLC who may benefit from the nivolumab + ipilimumab combination Full results of the study to follow
53 Small cell lung cancer
54 New research holds promise for patients with small cell lung cancer (SCLC) Sabari JK, et al. Nat Rev Clin Oncol. 2017;14(9):
55 Potential benefit of immunotherapy in treatment of patients with SCLC Positive initial results from studies of nivolumab and pembrolizumab reported in NCCN guidelines include nivolumab +/- ipilimumab (Yervoy ) for treatment of patients with previously treated SCLC Based on Checkmate 032 trial 5 1. Antonia SJ, et al. J Clin Oncol. 2015; 33 (Suppl). Abstract Ott PA, et al. J Clin Oncol. 2015;33 (Suppl). Abstract Calvo E, et al. Presented at: 2015 European Cancer Congress; September 25-29; Vienna, Austria. Abstract Ott PA, et al. Presented at: 16th World Conference on Lung Cancer; September 6-9; Denver, CO. Abstract Antonia SJ, et al. Lancet Oncol. 2016;17(7):
56 Checkmate 032 trial Responses to immunotherapy did not seem to correlate with PD-L1 SCLC may have lower rate of PD-L1 expression than NSCLC Antonia SJ, et al. Lancet Oncol. 2016;17(7):
57 What s next for SCLC? Rova T is a DLL3-targeted antibody-drug conjugate with encouraging activity in SCLC Trininty trial is studying rova-t as third-line treatment Evidence indicates 80% of patients with SCLC are positive for DLL3 expression Lurbinectedin, is a new chemotherapy Atlantis trial of lurbinectedin + doxorubicin vs either topotecan or CAV (cyclophosphamide, doxorubicine, and vincristine) in patients with SCLC Tanaka K, et al. Lung Cancer. 2018;115:
58 Results with Rova-T Confirmed responses with Rova-T in the second-line and third-line setting of recurrent/ refractory SCLC Sabari JK, et al. Nat Rev Clin Oncol. 2017;14(9):
59 Guidelines updated based on new staging and techniques New staging system applied - January AJCC Cancer Staging Manual, Eight Edition, 2016 Management of nodules seen on scans 1 Updated guidelines to manage solid nodules on chest x-ray Updates to SCLC guidelines 2 Radiation therapy, eg, use of more advanced techniques Treatment of brain metastasis Adjuvant treatments and monitoring 1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology (NCCN guidelines ) Non-small Cell Lung Cancer. Version Published January 17, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology (NCCN guidelines ) Small Cell Lung Cancer. Version Published January 17, 2018.
60 CAR-T cell therapy
61 What s supposed to happen: T-cells recognize cancer cells as foreign But how do they do that? = PD-1 *This was one of Joan s many over-simplifications
62 What s supposed to happen: T-cells recognize cancer cells as foreign But how do they do that? = PD-1 *How they recognize the cancer cells was one of Joan s many over-simplifications
63 By recognizing proteins on the tumor cell as abnormal, or foreign. To do this, they need to have the proper receptor, like a hook and chain = PD-1 *This was one of Joan s many over-simplifications
64 T-cells need BOTH to see the cancer cell they need to have their PDL1 receptors open, AND they need to hook up to the cancer cell = PD-1 *This was one of Joan s many over-simplifications
65 But what happens if the T cells don t have the proper receptor? = PD-1 *This was one of Joan s many oversimplifications
66 CAR-T makes the proper receptor on the patient s T cells Image from MSKCC; available online at: mskcc.org/blog/car-t-cell-therapy-growing-area-research
67 CAR-T is an exciting new approach to treating cancer Cells are taken from the patient, filtered, and reprogramed to express the correct hook to target the cancer cell They are then grown and multiplied in the lab, and then returned to the patient Once returned to the patient, the cells can continue multiplying and could fight disease for months or years Two CAR-T cell therapies are FDA approved for blood cancers (2017) CAR=chimeric antigen receptor
68 Key take-aways Advances in treatments for lung cancer Happened through research! Incredible advances have been made But, more research is needed to improve survival!
69 Building a movement WE CANNOT DO IT WITHOUT YOU There is strength in numbers!! Participating in this conference is a first step.
70 QUESTIONS?
71 THANK YOU!
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers TM Content is consistent with the Oncology Nursing Society Standards and Guidelines. The ONS Seal of Approval does not
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationNon-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationUNDERSTANDING SQUAMOUS CELL LUNG CANCER
UNDERSTANDING SQUAMOUS CELL LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure This brochure
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationTARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
More informationIMMUNOTHERAPY FOR LUNG CANCER
IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Lung Cancer Basics... 2 Immunotherapy... 3 FDA Approved Immunotherapies...
More informationNew Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors
New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors Farah Brasfield, MD Chair, Regional Chiefs of Oncology Kaiser Permanente Jennifer Chang, PharmD, MPH Supervisor, Drug Information Services
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationPersonalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationUpdates in Lung Cancer
Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationUpdates in Lung Cancer. J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute
Updates in Lung Cancer J. Tanner Ringley, PharmD, BCOP, CPP Levine Cancer Institute Learning Objectives: Discuss incorporation of liquid biopsies into practice and interpretation of immunotherapy biomarker
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More information3/13/2018. Case 1. Multidisciplinary Management of Cancers Thoracic Oncology Tumor Board
Multidisciplinary Management of Cancers Thoracic Oncology Tumor Board Matthew Gubens, MD MS, UC San Francisco, Chair Julia Rotow, MD, UC San Francisco, Fellow Colin Blakely, MD PhD, UC San Francisco GigI
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationAlimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationCorporate Medical Policy
Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationREPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2018 CHICAGO: RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital KU Leuven and Leuven Lung Cancer Group OUR 10 MESSAGE HIGHLIGHTS 1/ Advanced NSCLC 1 st line: IO
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationMICROSCOPY PREDICTIVE PROFILING
Immunomodulatory therapy in NSCLC: a year into clinical practice Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor to and speaker
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmunotherapy and Lung Cancer
Immunotherapy and Lung Cancer This booklet explains how immunotherapy uses the body s own natural defenses to treat lung cancer. So far, immunotherapy is approved for non-small cell lung cancer (NSCLC)
More informationESMO 2017 CONGRESS September 2017 Madrid, Spain. Developed in association with the European Thoracic Oncology Platform
Developed in association with the European Thoracic Oncology Platform ESMO 2017 CONGRESS Congress 8 12 September 2017 Madrid, Spain Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationCase Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationimmunotherapy a guide for the patient
immunotherapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2 immunotherapy... 5 Checkpoint Inhibitors... 6-9 Monoclonal Antibodies... 9 Vaccines... 10 Adoptive T-Cell
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationINITIAL SYSTEMIC TREATMENT IN STAGE IV NON-SMALL CELL LUNG CANCER
INITIAL SYSTEMIC TREATMENT IN STAGE IV NON-SMALL CELL LUNG CANCER Fran Maguire, MPH, PhD candidate California Cancer Reporting and Epidemiologic Surveillance (CalCARES) Program NAACCR Annual Conference
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationClinical Policy Title: Advanced non-small cell lung cancer with TKI and PD-1 drugs
Clinical Policy Title: Advanced non-small cell lung cancer with TKI and PD-1 drugs Clinical Policy Number: 05.02.11 Effective Date: March 1, 2017 Initial Review Date: February 15, 2017 Most Recent Review
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationNewest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationLUNG CANCER IN FOCUS. ALK Inhibitors in Non Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced?
LUNG CANCER IN FOCUS Current Developments in the Management of Section Editor: Mark A. Socinski, MD ALK Inhibitors in Non Small Cell : How Many Are Needed and How Should They Be Sequenced? Alice T. Shaw,
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationIntroducción. Enric Carcereny ICO Badalona-Hospital Germans Trias i Pujol
Introducción Enric Carcereny ICO Badalona-Hospital Germans Trias i Pujol Introducción Cáncer de pulmón: la neoplasia más frecuente y la principal causa de muerte relacionada con el cáncer. GLOBOCAN 2012
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More information